Phase 2b JAMA Data and New Financing Tools Could Be A Game Changer For GH Research (GHRS)

Simply Wall St.05-18

GH Research PLC recently reported a wider Q1 2026 net loss of US$18.97 million while advancing GH001 for treatment-resistant depression, including publishing positive Phase 2b data in JAMA Psychiatry ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636002395?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-05-18 15:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636002395","market":"sg","top_or_hot":-1,"title":"Phase 2b JAMA Data and New Financing Tools Could Be A Game Changer For GH Research (GHRS)","media":"Simply Wall St.","content":"<div>\n<p>GH Research PLC recently reported a wider Q1 2026 net loss of US$18.97 million while advancing GH001 for treatment-resistant depression, including publishing positive Phase 2b data in JAMA Psychiatry ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/phase-2b-jama-data-and-new-financing-tools-could-be-a-game-c\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Phase 2b JAMA Data and New Financing Tools Could Be A Game Changer For GH Research (GHRS)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhase 2b JAMA Data and New Financing Tools Could Be A Game Changer For GH Research (GHRS)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-18 15:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/phase-2b-jama-data-and-new-financing-tools-could-be-a-game-c><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>GH Research PLC recently reported a wider Q1 2026 net loss of US$18.97 million while advancing GH001 for treatment-resistant depression, including publishing positive Phase 2b data in JAMA Psychiatry ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/phase-2b-jama-data-and-new-financing-tools-could-be-a-game-c\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GHRS","symbol_name":"GH Research PLC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/phase-2b-jama-data-and-new-financing-tools-could-be-a-game-c","article_id":"2636002395","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/phase-2b-jama-data-and-new-financing-tools-could-be-a-game-c","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2636002395","pubTimestamp":1779089511,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"GH Research PLC recently reported a wider Q1 2026 net loss of US$18.97 million while advancing GH001 for treatment-resistant depression, including publishing positive Phase 2b data in JAMA Psychiatry and completing key Phase 1 studies.\nAn interesting aspect of this update is how the company has paired clinical progress with expanded financing flexibility, adding a US$200 million at-the-market facility and a US$400 million universal shelf to support its late-stage development plans.\nWith this...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"GHRS":"GH Research PLC","BK4551":"寇图资本持仓","BK4007":"制药","GH":"Guardant Health Inc.","BK4196":"保健护理服务","AIPO":"Defiance AI and Power Infrastructure ETF","BK4588":"碎股","BK4539":"次新股","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓"},"translate_title":"2b期JAMA数据和新融资工具可能会改变GH研究(GHRS)的游戏规则","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1.5,"GHRS":1.5,"AIPO":0.61},"content_text":"GH Research PLC recently reported a wider Q1 2026 net loss of US$18.97 million while advancing GH001 for treatment-resistant depression, including publishing positive Phase 2b data in JAMA Psychiatry and completing key Phase 1 studies. An interesting aspect of this update is how the company has paired clinical progress with expanded financing flexibility, adding a US$200 million at-the-market facility and a US$400 million universal shelf to support its late-stage development plans. With this backdrop, we’ll examine how the Phase 2b JAMA Psychiatry publication for GH001 reshapes GH Research’s investment narrative. Uncover the next big thing with 27 elite penny stocks that balance risk and reward.AdvertisementWhat Is GH Research's Investment Narrative?To own GH Research today, you have to believe that a single late‑stage asset, GH001 for treatment‑resistant depression, can eventually justify a US$0‑revenue, loss‑making biotech valued at a relatively rich price‑to‑book multiple. The recent JAMA Psychiatry Phase 2b publication and completion of key Phase 1 device and U.S. IND‑opening studies help crystallize the near‑term catalyst path around Phase 3 initiation and future regulatory interactions, which is what the market appears to be rewarding after a very large 1‑year total return. At the same time, the wider Q1 2026 loss and the new US$200 million ATM plus US$400 million shelf reinforce that this story now hinges even more on continued access to equity capital, with dilution risk moving to the foreground. Overall, the latest update sharpens the upside narrative but does not remove the binary clinical and financing risks that still define the stock. However, the expanded funding options come with one risk many shareholders might be underestimating.\n\nInsights from our recent valuation report point to the potential overvaluation of GH Research shares in the market.Exploring Other PerspectivesGHRS 1-Year Stock Price Chart Two Simply Wall St Community fair value views span roughly US$4 to US$41, underscoring how far apart people are on GH Research. Set those against the heavy cash burn and dilution risk discussed above and you can see why it pays to weigh several viewpoints before forming a view on the stock.Explore 2 other fair value estimates on GH Research - why the stock might be worth as much as 93% more than the current price!The Verdict Is YoursDisagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your GH Research research is our analysis highlighting 2 important warning signs that could impact your investment decision.Our free GH Research research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate GH Research's overall financial health at a glance.No Opportunity In GH Research?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Capitalize on the AI infrastructure supercycle with our selection of the 42 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636002395","isCrawlerRequest":true}